PT - JOURNAL ARTICLE AU - Mayen Briggs AU - Kieren SJ Allinson AU - Maura Malpetti AU - Maria Grazia Spillantini AU - James Benedict Rowe AU - Sanne Simone Kaalund TI - Validation of the new pathology staging system for progressive supranuclear palsy AID - 10.1101/2021.01.18.21250017 DP - 2021 Jan 01 TA - medRxiv PG - 2021.01.18.21250017 4099 - http://medrxiv.org/content/early/2021/01/25/2021.01.18.21250017.short 4100 - http://medrxiv.org/content/early/2021/01/25/2021.01.18.21250017.full AB - Progressive supranuclear palsy (PSP) is a neurodegenerative disorder associated with neuroglial accumulation of 4-repeat tau protein. Kovacs et al. have recently proposed a new semi-quantitative staging system to categorise the severity of PSP pathology, using the distribution of tau aggregates as it progresses from subcortical to cerebellar and cortical regions. Here, we test the new PSP pathology staging system in an independent series of PSP, and test the potential association between pathology stage and clinical severity at death. We include tissue from 35 people with a clinical diagnosis of PSP (including N=25 with Richardson’s syndrome and N=10 with other phenotypes). Donors had attended longitudinal clinical studies at the Cambridge Centre Parkinson-plus including assessment of clinical severity by the PSP rating scale (PSPRS) and cognitive performance by the revised Addenbrooke’s Cognitive Examination (ACE-R). We rated tau pathology from none-to-severe in six regions. We focused on (I) astrocytic tau inclusions in striatum, frontal and occipital regions, and (II) neuronal and oligodendroglia tau inclusions in globus pallidus, subthalamic nucleus, and cerebellum. Thirty-two cases (91%) readily conformed to the new staging system, ranging from stage 2 to 6. Staging system applied to brains from people with different clinical phenotypes of PSP. Neuropathology stages correlated with clinical severity at death using both PSPRS and ACE-R, weighted for the interval between last assessment and donation. Our study supports the proposed sequential distribution of tau aggregates in PSP pathology, and the hypothesised relationship between clinical and neuropathological severity. For future studies, in order to standardise rating between centres, we propose a set of operational criteria for region-specific thresholds or tau burden, and a visual guide.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by the Cambridge Brain Bank, Wellcome Trust (103838/Z/14/Z); Medical Research Council (Ref: 146281), and the Cambridge Centre for Parkinson plus (RG95450). The Cambridge Brain Bank is supported by the NIHR Cambridge Biomedical Research Centre.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study ethics was approved by the Health Research Authority, NHS, England (IRAS- 202 802, Neurodegeneration Research in Dementia). The PiPPIN (Pick's Disease and Progressive Supranuclear Palsy: Prevalence and Incidence) Study was approved by Cambridge's research ethics committee. The study was conducted in accordance with the 1964 Helsinki declaration.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used are available from the corresponding author on reasonable request.